BUD23 promote the cell proliferation ability by affecting the PPAR signaling pathways: evidence from the online dataset and cell experiment

Abstract Introduction Prostate cancer is a major public health challenge for men worldwide, being the second most common cancer diagnosis and the fifth leading cause of cancer-related deaths among men. The etiology of prostate cancer is multifactorial, with age, genetic predispositions, and lifestyl...

Full description

Saved in:
Bibliographic Details
Main Authors: Tao Huang, Binbin Jiao, Zhenkai Luo, Xiaolei Zhang, Zengjun Wang
Format: Article
Language:English
Published: Springer 2024-12-01
Series:Discover Oncology
Online Access:https://doi.org/10.1007/s12672-024-01648-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846136991513575424
author Tao Huang
Binbin Jiao
Zhenkai Luo
Xiaolei Zhang
Zengjun Wang
author_facet Tao Huang
Binbin Jiao
Zhenkai Luo
Xiaolei Zhang
Zengjun Wang
author_sort Tao Huang
collection DOAJ
description Abstract Introduction Prostate cancer is a major public health challenge for men worldwide, being the second most common cancer diagnosis and the fifth leading cause of cancer-related deaths among men. The etiology of prostate cancer is multifactorial, with age, genetic predispositions, and lifestyle factors playing critical roles. The role of the peroxisome proliferator-activated receptors (PPARs) in prostate cancer remains complex and not fully elucidated. Methods Transcriptomic data from The Cancer Genome Atlas (TCGA) were utilized for this study. The data were analyzed using single-sample Gene Set Enrichment Analysis (ssGSEA), Gene Ontology (GO) enrichment analysis, KEGG pathway analysis, and Gene Set Enrichment Analysis (GSEA). A prognosis-prediction model was constructed using Cox regression and LASSO analysis. Functional experiments, including Western blotting, quantitative PCR (qPCR), Cell Counting Kit-8 (CCK-8) assays, and EdU incorporation assays, were performed to validate the role of BUD23 in prostate cancer. Results Significant differences were observed in the immune microenvironment and HLA gene expression profiles between high and low PPAR expression groups in prostate cancer. The high PPAR group exhibited a less active immune microenvironment with higher fractions of immunosuppressive T regulatory cells (Tregs). A robust prognostic model identified key genes, including BUD23, associated with patient survival. Elevated BUD23 expression was correlated with more aggressive clinical features such as advanced pathological stages, nodal metastasis, and higher Gleason scores. Knockdown of BUD23 in PC-3 and LNCaP prostate cancer cell lines significantly inhibited cell proliferation. Western blotting and qPCR confirmed effective BUD23 knockdown, and CCK-8 and EdU assays demonstrated reduced cell proliferation. BUD23 knockdown resulted in significant reductions in PPAR-α, PPAR-β, and PPAR-γ protein levels, suggesting a regulatory axis between BUD23 and PPARs in prostate cancer. Conclusion The study highlights the distinct roles of PPARα, PPARβ/δ, and PPARγ in prostate cancer progression and their potential as therapeutic targets. Elevated BUD23 expression is associated with aggressive prostate cancer features and patient survival, making it a potential prognostic biomarker. The knockdown of BUD23 not only inhibited cell proliferation but also reduced the expression of PPAR-related proteins, indicating a potential regulatory axis between BUD23 and PPARs. These findings suggest that targeting BUD23 could modulate PPAR signaling and inhibit tumor growth in prostate cancer.
format Article
id doaj-art-6f23a8d40f08428ab3695388c3266ef4
institution Kabale University
issn 2730-6011
language English
publishDate 2024-12-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-6f23a8d40f08428ab3695388c3266ef42024-12-08T12:34:51ZengSpringerDiscover Oncology2730-60112024-12-0115111410.1007/s12672-024-01648-zBUD23 promote the cell proliferation ability by affecting the PPAR signaling pathways: evidence from the online dataset and cell experimentTao Huang0Binbin Jiao1Zhenkai Luo2Xiaolei Zhang3Zengjun Wang4Department of Urology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Urology, Beijing Chao-Yang Hospital, Capital Medical UniversityZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of SciencesDepartment of Urology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Urology, The First Affiliated Hospital of Nanjing Medical UniversityAbstract Introduction Prostate cancer is a major public health challenge for men worldwide, being the second most common cancer diagnosis and the fifth leading cause of cancer-related deaths among men. The etiology of prostate cancer is multifactorial, with age, genetic predispositions, and lifestyle factors playing critical roles. The role of the peroxisome proliferator-activated receptors (PPARs) in prostate cancer remains complex and not fully elucidated. Methods Transcriptomic data from The Cancer Genome Atlas (TCGA) were utilized for this study. The data were analyzed using single-sample Gene Set Enrichment Analysis (ssGSEA), Gene Ontology (GO) enrichment analysis, KEGG pathway analysis, and Gene Set Enrichment Analysis (GSEA). A prognosis-prediction model was constructed using Cox regression and LASSO analysis. Functional experiments, including Western blotting, quantitative PCR (qPCR), Cell Counting Kit-8 (CCK-8) assays, and EdU incorporation assays, were performed to validate the role of BUD23 in prostate cancer. Results Significant differences were observed in the immune microenvironment and HLA gene expression profiles between high and low PPAR expression groups in prostate cancer. The high PPAR group exhibited a less active immune microenvironment with higher fractions of immunosuppressive T regulatory cells (Tregs). A robust prognostic model identified key genes, including BUD23, associated with patient survival. Elevated BUD23 expression was correlated with more aggressive clinical features such as advanced pathological stages, nodal metastasis, and higher Gleason scores. Knockdown of BUD23 in PC-3 and LNCaP prostate cancer cell lines significantly inhibited cell proliferation. Western blotting and qPCR confirmed effective BUD23 knockdown, and CCK-8 and EdU assays demonstrated reduced cell proliferation. BUD23 knockdown resulted in significant reductions in PPAR-α, PPAR-β, and PPAR-γ protein levels, suggesting a regulatory axis between BUD23 and PPARs in prostate cancer. Conclusion The study highlights the distinct roles of PPARα, PPARβ/δ, and PPARγ in prostate cancer progression and their potential as therapeutic targets. Elevated BUD23 expression is associated with aggressive prostate cancer features and patient survival, making it a potential prognostic biomarker. The knockdown of BUD23 not only inhibited cell proliferation but also reduced the expression of PPAR-related proteins, indicating a potential regulatory axis between BUD23 and PPARs. These findings suggest that targeting BUD23 could modulate PPAR signaling and inhibit tumor growth in prostate cancer.https://doi.org/10.1007/s12672-024-01648-z
spellingShingle Tao Huang
Binbin Jiao
Zhenkai Luo
Xiaolei Zhang
Zengjun Wang
BUD23 promote the cell proliferation ability by affecting the PPAR signaling pathways: evidence from the online dataset and cell experiment
Discover Oncology
title BUD23 promote the cell proliferation ability by affecting the PPAR signaling pathways: evidence from the online dataset and cell experiment
title_full BUD23 promote the cell proliferation ability by affecting the PPAR signaling pathways: evidence from the online dataset and cell experiment
title_fullStr BUD23 promote the cell proliferation ability by affecting the PPAR signaling pathways: evidence from the online dataset and cell experiment
title_full_unstemmed BUD23 promote the cell proliferation ability by affecting the PPAR signaling pathways: evidence from the online dataset and cell experiment
title_short BUD23 promote the cell proliferation ability by affecting the PPAR signaling pathways: evidence from the online dataset and cell experiment
title_sort bud23 promote the cell proliferation ability by affecting the ppar signaling pathways evidence from the online dataset and cell experiment
url https://doi.org/10.1007/s12672-024-01648-z
work_keys_str_mv AT taohuang bud23promotethecellproliferationabilitybyaffectingthepparsignalingpathwaysevidencefromtheonlinedatasetandcellexperiment
AT binbinjiao bud23promotethecellproliferationabilitybyaffectingthepparsignalingpathwaysevidencefromtheonlinedatasetandcellexperiment
AT zhenkailuo bud23promotethecellproliferationabilitybyaffectingthepparsignalingpathwaysevidencefromtheonlinedatasetandcellexperiment
AT xiaoleizhang bud23promotethecellproliferationabilitybyaffectingthepparsignalingpathwaysevidencefromtheonlinedatasetandcellexperiment
AT zengjunwang bud23promotethecellproliferationabilitybyaffectingthepparsignalingpathwaysevidencefromtheonlinedatasetandcellexperiment